SEC Info - Acumen Pharmaceuticals, Inc. - ‘S-3’ on 3/27/24

SEC Info℠

Home

Help

Please Sign In

Acumen Pharmaceuticals, Inc. – ‘S-3’ on 3/27/24 – ‘EX-23.1’

On: Wednesday, 3/27/24, at 4:34pm ET · Accession #: 1628280-24-13290 · File #: 333-278280

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/27/24  Acumen Pharmaceuticals, Inc.      S-3                    8:1.2M                                   Workiva Inc Wde… FA01/FA

Registration Statement – Securities for a Transaction — Form S-3 — SA’33

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-3         Registration Statement - Securities for a           HTML    330K 
                Transaction                                                      
 3: EX-4.2      Instrument Defining the Rights of Security Holders  HTML    375K 
 4: EX-4.4      Instrument Defining the Rights of Security Holders  HTML    125K 
 5: EX-4.5      Instrument Defining the Rights of Security Holders  HTML    161K 
 6: EX-4.6      Instrument Defining the Rights of Security Holders  HTML    148K 
 7: EX-5.1      Opinion of Counsel re: Legality                     HTML     23K 
 8: EX-23.1     Consent of Expert or Counsel                        HTML      7K 
 2: EX-FILING FEES  Filing Fees                                     HTML     35K

‘EX-23.1’ — Consent of Expert or Counsel

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

C: C:

Document

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the reference to our firm under the caption “Experts” in the Registration Statement (Form S-3) and related Prospectuses of Acumen Pharmaceuticals, Inc. for the registration of $200,000,000 of its common stock, preferred stock, debt securities, and warrants and to the incorporation by reference therein of our report dated March 26, 2024, with respect to the financial statements of Acumen Pharmaceuticals, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2023, filed with the Securities and Exchange Commission.


/s/ *Ernst & Young LLP*

Tysons, Virginia
March 26, 2024

Dates Referenced Herein and Documents Incorporated by Reference

This ‘S-3’ Filing	Date	Other Filings

Filed on:	3/27/24	S-8
	3/26/24	10-K, 8-K
	12/31/23	10-K
		List all Filings

9 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/26/24  Acumen Pharmaceuticals, Inc.      10-K       12/31/23   83:61M
 2/01/24  Acumen Pharmaceuticals, Inc.      8-K:5,7,9   2/01/24   11:721K
 3/27/23  Acumen Pharmaceuticals, Inc.      10-K       12/31/22   73:25M
 3/15/23  Acumen Pharmaceuticals, Inc.      8-K:5,9     3/09/23   11:391K
 4/27/22  Acumen Pharmaceuticals, Inc.      DEF 14A     6/15/22    1:846K                                   Donnelley … Solutions/FA
 3/28/22  Acumen Pharmaceuticals, Inc.      10-K       12/31/21   73:12M                                    Donnelley … Solutions/FA
 7/07/21  Acumen Pharmaceuticals, Inc.      8-K:5,9     7/06/21    3:155K                                   Donnelley … Solutions/FA
 6/28/21  Acumen Pharmaceuticals, Inc.      8-A12B                 1:15K                                    Donnelley … Solutions/FA
 6/09/21  Acumen Pharmaceuticals, Inc.      S-1                   10:5.2M                                   Donnelley … Solutions/FA

↑Top

Filing Submission 0001628280-24-013290 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)